A population-based retrospective cohort study patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE. This included maternal/infant rehospitalization, malformations and mortality. 

The population under study was derived from the Washington State linked vital-hospital discharge records (between 1987-2014) and included women with RA (N=1,223) and SLE (N=1,354) and a comparatory group of unexposed women with singleton births.

BE COMPLETE is published, showing that bimekizumab (BMK), a selective dual inhibitor of interleukin (IL)-17F and IL-17A, results in superior improvement in both skin and joint outcomes in psoriatic arthritis (PsA) patients who have previously failed treatment with a tumour necrosis factor-α (TNFα) inhibitor.